A fraction isolated from Ehrlich ascites carcinoma as an antitumor and differentiating agent against human leukemic cell ML-2.
Lipopolysaccharide fraction isolated from Ehrlich ascites carcinoma (E-LPS) was investigated as an antitumor agent against human leukemia cell ML-2. Marked cell growth inhibition was observed with ML-2 cell accompanied by inhibition of DNA synthesis and perturbation of cell cycle. Induction of differentiation in treated ML-2 cells was observed as indicated by morphological maturation, NBT reducing activity and indirect immunofluorescence.
Sur
P
P
Department of Pharmacology and Experimental Therapeutics, Indian Institute of Chemical Biology, Jadavpur University, Calcutta. iichbio@sias101.vsnl.net.in
Nandi
N
N
Ghosh
P
P
Ghosh
N C
NC
D000818:Animals; D000970:Antineoplastic Agents / Q000302:isolation & purification / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000737:chemistry / Q000378:metabolism*; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D005455:Fluorescent Antibody Technique; D006131:Growth Inhibitors / Q000494:pharmacology; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D008070:Lipopolysaccharides / Q000302:isolation & purification / Q000494:pharmacology*; D051379:Mice; D009368:Neoplasm Transplantation; D014407:Tumor Cells, Cultured / Q000187:drug effects*
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D006131:Growth Inhibitors; D008070:Lipopolysaccharides